Needham, MA, March 26, 2009 / b3c newswire / - Cambridge Healthtech Institute’s Fifth Annual Biomarker World Congress will be held May 27-29, 2009 at the Loews Philadelphia Hotel, Philadelphia, Pennsylvania. The advance registration deadline for this event is April 10, 2009.
The signature event in Cambridge Healthtech Institute's Biomarker Series, The Biomarker World Congress 2009 (www.biomarkerworldcongress.com) is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers-making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. The Congress also offers a balance of scientific sessions covering the latest research and strategic presentations and brainstorming sessions for the decision makers. Now in its fifth year, the Biomarker World Congress is the leading annual meeting dedicated to biomarker research and implementation that consistently delivers a cutting-edge agenda, 500+ senior delegates, and a sold-out exhibit hall.
Who Should Attend:
Researchers and Executives working in the following areas should plan on attending
- Molecular Diagnostics
- Assay Development
- Personalized Medicine
- Clinical Pharmacology
- Translational Medicine
- Safety Assessment
- Clinical Trials
- Biomarker Qualification
- Oncology Drugs & Diagnostics
Pre-Conference Events:
Executive ThinkTank: Collaborations, Consortia, and Funding Opportunities in Biomarker Development
Short Course: Fit-for-Purpose Biomarker Assay Development & Validation
Workshop: Biomarkers for Cancer Drug Development
DISTINGUISHED FACULTY:
John Allinson, FIBMS, Laboratory Director, Veeda Clinical Research
Stewart Bates, Ph.D., Director, Stevenage Core Technologies Group, Discovery Technology Group, GlaxoSmithKline
John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.
Michael E. Burczynski, Ph.D., Associate Director, Biomarker Lab, Clinical Translational Medicine, Wyeth Pharmaceuticals
C. Thomas Caskey, M.D., F.A.C.P., Director & Chief Executive Officer, The Brown Foundation Institute of Molecular Medicine and Genetics, The University of Texas, Health Science Center at Houston
Maryellen de Mars, Ph.D., Director, Clinical Biomarkers, The Critical Path Institute
Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories
Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson
Iman El-Hariry, M.D., Ph.D., Group Director, Oncology MDC, GlaxoSmithKline Research & Development
Robert E. Epstein, M.D., M.S., Senior Vice President, Medical & Analytical Affairs; Chief Medical Officer, Medco Health Solutions, Inc.
Giora Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research
Paul J. Fielder, Ph.D., Senior Director & Senior Scientist, Early Development Pharmacokinetics, Pharmacodynamic and Bioanalytical Sciences, Genentech, Inc.
Mark Fidock, Ph.D., Head, Biochemical and Molecular BioMarkers, Experimental Biological Sciences, Pfizer Limited
Dorothee Foernzler, Ph.D., Biomarker-Experimental Medicine Leader, F. Hoffmann-La Roche AG
Alberto Gutierrez, Ph.D., Deputy Director, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), U.S. Food and Drug Administration
Yiwu He, Ph.D., Senior Program Officer, Global Health Discovery, Bill & Melinda Gates Foundation
Phil Hewitt, Ph.D., Head, Molecular Toxicology, Institute of Toxicology, Merck KGaA
Darren Hodgson, Ph.D., Biomics Advisor, Oncology Therapy Area, AstraZeneca
Arthur L. Holden, Ph.D., Chairman and Chief Executive Officer, International Serious Adverse Event Consortium, Ltd. (SAEC)
Martina Kaufmann, Ph.D., Biomarker Project Leader, Early Clinical Development Oncology, Novartis Pharma AG
Geert Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.
Chetan Lathia, Ph.D., Director, Global Clinical Pharmacology, Bayer Corp.
Kwan Lee, Ph.D., Senior Director, Department of Biostatistics and Data Management, GlaxoSmithKline
Francois Legay, Ph.D., Global Head, Marker Localization & Assays, Novartis Pharma AG
Lawrence J. Lesko, Ph.D., F.C.P., Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Klaus Lindpaintner, M.D., M.P.H., Head, Medical Genomics & Vice President, Research, F. Hoffmann-La Roche AG
Helen M. Moore, Ph.D., Director, Biospecimen Research Network, National Cancer Institute, National Institutes of Health
Patrick Y. Mueller, Ph.D., Project Leader, Safety Assessment, Novartis Pharma AG
Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
Christoph Petry, Ph.D., Head, Molecular Research Germany, Siemens Healthcare Diagnostics Products GmbH
Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. Food and Drug Administration
Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals
Brian B. Spear, Ph.D., Director, Scientific Affairs, Global Pharmaceutical Research and Development, Abbott Labs
Linda C. Surh, M.D., Ph.D., FRCPC, Director, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline, UK
Ole Vesterqvist, Ph.D., Senior Director, Biomarker Lab & Outsourcing, Clinical Translational Medicine, Wyeth Research
Xinkang Wang, Ph.D., Head, Imaging Biomarker Group, Discovery Translational Medicine, Wyeth Research
Jeffrey Waring, Ph.D., Associate Research Fellow & Group Leader, Cellular & Molecular Toxicology, Abbott Labs
David Wholley, Director, Biomarkers Consortium, Foundation for the National Institutes of Health
- Hans Winkler, Ph.D., Senior Director & Global Head, Oncology Biomarkers, Pharmaceutical Research & Development, Johnson & Johnson
About Cambridge Healthtech Institute - www.healthtech.com
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
For more information please visit: www.biomarkerworldcongress.com
